Mitochondrial Peptide
Advanced cellular energy and metabolic optimization
MOTS-c is a mitochondrial-derived peptide that enhances cellular energy production, improves metabolic function, and supports healthy aging by optimizing mitochondrial efficiency. This naturally occurring peptide regulates glucose metabolism, promotes fat oxidation, and enhances exercise performance by activating critical metabolic pathways at the cellular level.
10mg
Therapeutic Dose
SC/IM
Administration
3-7x
Weekly Dosing
4-12
Week Protocols
Available Dosing
Premium pharmaceutical-grade MOTS-c peptide designed for optimal cellular energy production and metabolic enhancement through targeted mitochondrial optimization.
Standard therapeutic dosage
Ideal For
Individuals seeking enhanced metabolic function, improved exercise performance, increased cellular energy, optimized glucose metabolism, fat loss support, and healthy aging through mitochondrial optimization.
The Science
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a recently discovered mitochondrial-derived peptide that plays a crucial role in cellular energy metabolism and metabolic homeostasis. This 16-amino acid peptide is encoded within the mitochondrial genome and represents a novel class of signaling molecules that communicate between mitochondria and the nucleus to regulate whole-body metabolism.
MOTS-c functions as a powerful metabolic regulator by activating AMPK (AMP-activated protein kinase), a master metabolic switch that enhances glucose uptake, promotes fat oxidation, and improves insulin sensitivity. By optimizing mitochondrial function, MOTS-c increases cellular energy production (ATP), reduces oxidative stress, and supports metabolic flexibility—the ability to efficiently switch between burning carbohydrates and fats for fuel.
Research demonstrates that MOTS-c levels decline with age, contributing to age-related metabolic dysfunction and decreased cellular energy. Supplementation with MOTS-c has shown remarkable potential for improving exercise performance, enhancing recovery, supporting healthy weight management, regulating blood sugar levels, and promoting longevity by restoring youthful mitochondrial function. This makes MOTS-c particularly valuable for individuals seeking to optimize metabolic health, enhance athletic performance, support healthy aging, or address metabolic concerns such as insulin resistance and metabolic syndrome.
Book a Consultation
How It Works
MOTS-c enhances cellular metabolism through targeted activation of energy-regulating pathways, improving mitochondrial efficiency and metabolic flexibility for superior energy production and metabolic health.
Activates AMPK signaling to enhance glucose uptake, promote fat oxidation, and improve cellular energy metabolism, acting as a metabolic master switch for optimal energy balance.
Improves insulin sensitivity and glucose metabolism while promoting metabolic flexibility, enabling efficient fuel utilization and supporting healthy blood sugar regulation.
Enhances mitochondrial efficiency and ATP production while reducing oxidative stress, supporting cellular energy generation and protecting against age-related mitochondrial decline.
Clinical Benefits
Optimizes mitochondrial ATP production for increased cellular energy, reducing fatigue and enhancing overall vitality and physical performance capacity.
Enhances endurance, strength, and recovery by optimizing energy metabolism and reducing exercise-induced fatigue for superior athletic performance and training adaptations.
Improves insulin sensitivity, glucose metabolism, and metabolic flexibility, supporting healthy blood sugar regulation and efficient nutrient utilization.
Promotes fat oxidation and healthy weight management by enhancing metabolic rate and improving the body’s ability to utilize fat as fuel.
Counteracts age-related metabolic decline by restoring mitochondrial function, supporting longevity, and promoting cellular health throughout the aging process.
Supports cardiovascular function and metabolic health by improving vascular function, reducing oxidative stress, and enhancing overall cardio-metabolic resilience.
Your Journey
Our medical team guides you through every step—from initial consultation to ongoing optimization.
Comprehensive metabolic evaluation including health history, fitness goals, and current metabolic function to determine candidacy.
Complete metabolic panel, glucose tolerance assessment, and baseline labs to establish your metabolic profile and track improvements.
Receive personalized MOTS-c dosing regimen tailored to your metabolic goals, activity level, and therapeutic objectives.
Regular follow-ups with metabolic testing, performance tracking, and protocol optimization to maximize results and ensure safety.
Safety & Candidacy
MOTS-c is a naturally occurring mitochondrial peptide with an excellent safety profile. Our medical team performs comprehensive metabolic assessments to ensure appropriate candidacy and optimal dosing for your individual needs.
100%
Naturally occurring mitochondrial peptide bioidentical to human MOTS-c
10+
Years of research validating safety and metabolic benefits
Questions
MOTS-c is a mitochondrial-derived peptide that regulates cellular energy metabolism by activating AMPK, a master metabolic switch. It enhances glucose uptake, promotes fat oxidation, improves insulin sensitivity, and optimizes mitochondrial function for increased cellular energy production. MOTS-c acts as a signaling molecule that communicates between mitochondria and the nucleus to regulate whole-body metabolism, supporting metabolic health, exercise performance, and healthy aging.
MOTS-c provides comprehensive metabolic benefits including enhanced cellular energy and reduced fatigue, improved exercise performance and endurance, better insulin sensitivity and glucose metabolism, support for healthy weight management and fat loss, increased metabolic flexibility, enhanced recovery from exercise, and protection against age-related metabolic decline. Many users also report improved mental clarity, sustained energy throughout the day, and better overall vitality. Clinical research supports its role in optimizing metabolic health and promoting longevity.
MOTS-c is administered via subcutaneous or intramuscular injection, typically 3-7 times per week depending on individual goals and response. The standard therapeutic dose is 10mg per injection, though dosing is personalized based on your metabolic profile, activity level, and treatment objectives. Most protocols run for 4-12 weeks, with some individuals benefiting from ongoing use or periodic cycles. Your BHRC physician will determine the optimal dosing schedule and duration for your specific needs.
Many individuals notice increased energy and improved exercise performance within the first 1-2 weeks of consistent use. Metabolic improvements such as enhanced insulin sensitivity and better glucose regulation typically become apparent within 2-4 weeks. More significant changes in body composition, endurance, and metabolic markers generally develop over 4-8 weeks of therapy. For optimal results in metabolic optimization and longevity support, protocols of 8-12 weeks are recommended, with benefits often sustained beyond the treatment period.
MOTS-c has an excellent safety profile with minimal reported side effects. Occasional mild injection site reactions may occur. Unlike anabolic compounds, MOTS-c does not affect hormonal balance and does not require post-cycle therapy. However, individuals with active metabolic disorders, certain chronic conditions, or those taking medications for diabetes should consult with their physician before starting therapy. Comprehensive medical evaluation and baseline metabolic testing ensure safe and appropriate use. There are no known significant drug interactions, but full medication disclosure is essential during consultation.
Yes, MOTS-c can be safely combined with other peptide therapies, hormone optimization, nutritional interventions, and exercise programs. Many patients stack MOTS-c with NAD+ for enhanced cellular energy and longevity benefits, with CJC-1295/Ipamorelin for body composition optimization, or as part of comprehensive metabolic health protocols. It’s also compatible with conventional medications and supplements, though your BHRC physician will review all current treatments to design an integrated protocol optimized for your metabolic goals and health objectives.
MOTS-c therapy is typically not covered by insurance as it’s considered preventive and regenerative medicine focused on metabolic optimization and longevity. BHRC offers transparent pricing and flexible payment options to make this innovative metabolic therapy accessible. Many patients find the investment worthwhile given the comprehensive benefits for energy, performance, metabolic health, and healthy aging. Our team can provide detailed cost information and discuss payment plans during your consultation.
Get Started
Schedule a consultation with our medical team to learn if MOTS-c peptide therapy is right for your wellness journey.
"*" indicates required fields
Or call us directly: +1 213-325-3373
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. MOTS-c is provided for metabolic optimization and wellness purposes under physician supervision. Individual results may vary. A consultation with our medical team and baseline laboratory testing are required to determine if this therapy is appropriate for you.
MOTS-c is a mitochondrial-derived peptide studied for its role in cellular energy metabolism and insulin sensitivity. At BHRC it is not sold as a standalone product you self-administer without oversight — it is prescribed as part of a monitored protocol built around your baseline labs and goals.
The structure matters more than the molecule. Most disappointing peptide outcomes trace back to no baseline labs, inconsistent administration, or an unrealistic timeline rather than to the peptide itself. For the full technical breakdown — dosing ranges, reconstitution math, syringe calculations and cycle structures — see our complete MOTS-c dosage guide.
Book a MOTS-c ConsultationResponse varies between individuals, and the timeline below reflects what patients on a supervised protocol commonly report rather than a guaranteed outcome. Your provider will set expectations specific to your labs, history and goals.
| Timeframe | What patients typically report |
|---|---|
| Weeks 1–2 | Little to no perceptible change. This is expected. Some patients notice mild injection-site tenderness that resolves with site rotation. |
| Weeks 3–4 | Commonly the first reported changes — steadier daytime energy and reduced post-exercise fatigue. Objective markers usually have not moved meaningfully yet. |
| Weeks 5–8 | Exercise tolerance and recovery are the most frequently reported improvements. If body composition is a goal, changes here are typically modest and depend heavily on training and nutrition. |
| Weeks 8–12 | Mid-cycle labs are re-drawn. Metabolic markers such as fasting insulin and HbA1c are assessed against baseline. Your provider decides whether to continue, adjust or cycle off. |
| After the cycle | A washout period is standard. Whether a second cycle is warranted is determined by what your follow-up labs and functional markers actually showed. |
MOTS-c occupies a specific niche. It is frequently confused with growth-hormone secretagogues and with GLP-1 medications, which do very different things. This comparison is intended to help you arrive at your consultation with better questions.
| Option | Primary use | Administration | Best suited to |
|---|---|---|---|
| MOTS-c | Mitochondrial and metabolic function, exercise capacity | Subcutaneous, 2–3×/week | Metabolically healthy patients focused on energy, performance and healthy aging |
| CJC-1295 / Ipamorelin | Growth hormone axis support, recovery, sleep quality | Subcutaneous, typically nightly | Patients whose primary concerns are recovery, body composition and sleep |
| Tesamorelin | Visceral adipose tissue reduction | Subcutaneous, daily | Patients with a specific visceral fat concern and appropriate labs |
| GLP-1 therapy (semaglutide, tirzepatide) | Clinically significant weight reduction, glycemic control | Subcutaneous, weekly | Patients whose primary goal is meaningful weight loss |
| NAD+ therapy | Cellular energy cofactor support | IV or subcutaneous | Patients pursuing energy and longevity protocols, often alongside other therapies |
These are not mutually exclusive, and combinations are common — but stacking multiplies both cost and risk, and should only be done under supervision with a clear rationale for each addition.
Monitoring is the part patients most often want to skip and the part that most determines whether a protocol was worth doing. A peptide cycle without measurement produces an anecdote, not a result.
If mid-cycle markers have not moved and you feel no functional difference, the appropriate response is to stop and reassess rather than extend the cycle or raise the dose. Your provider will make that call with you.
Yes. At BHRC, MOTS-c is prescribed and dispensed under provider supervision following a consultation and baseline labs. We do not sell it as an unsupervised product. Peptides marketed online as ‘research use only’ sit outside that framework and carry real sourcing, purity and legal risk.
Cost depends on your protocol — dose, cycle length, whether MOTS-c is used alone or alongside other therapies, and what lab work is required. Pricing is reviewed transparently during your consultation before anything is prescribed. Peptide therapy is generally not covered by insurance.
BHRC provides physician-supervised peptide therapy across its locations, including West Hollywood, West Los Angeles, Valencia, Paradise Valley and Summerlin. Consultations determine candidacy and protocol; ongoing monitoring is handled through your treating location.
MOTS-c is not an FDA-approved drug. It is available through compounding pharmacies and used off-label under provider supervision. Research in humans remains limited relative to established medications, which is precisely why supervision, baseline labs and follow-up monitoring matter.
They are not comparable therapies. GLP-1 medications are studied and prescribed primarily for clinically significant weight reduction and glycemic control. MOTS-c is studied for mitochondrial and metabolic function — energy, exercise capacity and insulin sensitivity. If substantial weight loss is your goal, a GLP-1 is far more likely to be the appropriate conversation.
Most patients who report changes describe them beginning somewhere between weeks three and six, usually as steadier energy or improved recovery rather than anything dramatic. Objective laboratory changes are assessed at mid-cycle. Anyone promising results in the first fortnight is overselling.
Yes, and it commonly is — frequently alongside growth-hormone secretagogues or NAD+ protocols. Every addition compounds both cost and risk, so each element should have a specific rationale. Stacking decisions are made in consultation, not assembled from forum protocols.
The most commonly reported are injection-site reactions — redness, tenderness or mild swelling — which usually resolve with proper site rotation and technique. Some patients report transient fatigue or GI discomfort early in a cycle. Anything persistent, severe or unexpected should be reported to your provider promptly.
Potentially, yes. Peptides are subject to WADA and USADA prohibited lists, and status can change. If you compete in a tested sport, verify current status against the governing list before starting any peptide protocol. Do not rely on general guidance for this — the consequences fall on the athlete.
A washout period is standard practice. Follow-up labs and functional markers are reviewed against your baseline, and that determines whether a further cycle is justified, whether the protocol should change, or whether MOTS-c was simply not the right tool for your goals.
MOTS-c is rarely the only thing worth considering. These are the therapies most often discussed alongside it, and the guide that covers the technical dosing detail.
The literature below is peer-reviewed background on MOTS-c and the mechanisms discussed on this page. It is provided so you can read the primary sources yourself. It is not evidence of any particular outcome at BHRC, and much of it is preclinical — animal or cell-culture work that has not been replicated in humans. Your provider will discuss what the evidence does and does not support for your situation.
Dosage & Protocol Library
Full MOTS-c dosing protocol plus the metabolic peptides most often run alongside it — exact schedules, titration and cycling.
